Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of the Marriage and Civil Partnership (Minimum Age) Act 2022 on birth rates amongst South Asian women in England.

The Medico-legal journal·2025

Same author

Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy.

PharmacoEconomics - open·2024

Same author

Developing a Natural History Model for Duchenne Muscular Dystrophy.

PharmacoEconomics - open·2023

Same author

NHS Trust Boards and Health and Well-being Boards: Do they play any role in the management of disparate levels of care for South Asian patients with Inflammatory Bowel Disease?

The Ulster medical journal·2023

Same author

Khan v Meadows [2021] UKSC 21 and its potential impact on clinical negligence cases.

The Medico-legal journal·2022

Same author

Jointly modelling longitudinally measured urinary human chorionic gonadotrophin and early pregnancy outcomes.

Scientific reports·2020

Search research articles

Related Experiment Videos

Meta-analysis: mortality in Crohn's disease.

C Canavan¹, K R Abrams, J F Mayberry

¹Digestive Diseases Centre, University Hospitals of Leicester, Leicester General Hospital, Gwendolen Road, Leicester. cc71@le.ac.uk

Alimentary Pharmacology & Therapeutics

|April 4, 2007

Summary

Crohn's disease patients face over 50% higher mortality than the general population. While mortality has improved, ongoing evaluation of clinical practices is needed to further reduce risks for Crohn's disease patients.

Related Experiment Videos

Area of Science:

Gastroenterology
Epidemiology
Public Health

Background:

Crohn's disease is a chronic inflammatory condition with significant health implications.
Understanding long-term mortality trends in Crohn's disease patients is crucial for clinical management and public health strategies.

Purpose of the Study:

To conduct a meta-analysis of published literature to determine the standardized mortality ratio (SMR) for Crohn's disease patients from 1970 to the present.
To assess temporal trends in mortality risk among individuals with Crohn's disease.

Main Methods:

A comprehensive literature search was performed using Medline and reference lists to identify relevant studies.
Studies reporting SMR for Crohn's disease patients were included. When multiple publications existed for the same patient cohort, the most recent was selected.

Main Results:

The meta-analysis of 13 identified papers revealed a pooled SMR of 1.52 (95% CI: 1.32 to 1.74, P < 0.0001), indicating a 52% higher mortality rate compared to the general population.
While meta-regression suggested a slight, non-significant decrease in SMR over the past 30 years (P = 0.08), most studies reported mortality higher than the general population.

Conclusions:

Age-adjusted mortality risk for Crohn's disease patients is substantially elevated, exceeding the general population by over 50%.
Although some improvements in mortality have been observed since the initial recognition of Crohn's disease, further research is warranted to evaluate the impact of recent clinical practice changes on patient outcomes.